Skip to main content
TipRanks
Go Ultimate75% OFF

Definitive Healthcare Corp (DH) AI Stock Analysis

78 Followers
DH

Definitive Healthcare Corp

(NASDAQ:DH)

Select Model
Rating:56Neutral
Price Target:$1.50â–²(11.94% Upside)
Action:reiterated
Date:11/06/26

The score is held back primarily by weak financial performance (large net losses, very negative ROE, and declining revenue) despite strong gross margins and positive cash flow. Technicals are a relative positive with the stock trading above major moving averages and a positive MACD, while the earnings call points to continued top-line pressure and weaker visibility even as profitability guidance improved. Valuation is difficult to support with a negative P/E and no dividend yield.

Positive Factors
High Gross MarginsHigh gross margins indicate attractive underlying economics in DH’s data and analytics offering. This provides room to fund product development, absorb commercial pressure, and expand operating profitability if revenue stabilizes, making margin structure a durable business strength.
Negative Factors
Sustained Revenue DeclinePersistent revenue contraction signals that DH is facing more than a single-quarter disruption, with subscription weakness and slower professional services demand limiting growth. Continued declines can reduce operating leverage, weaken reinvestment capacity, and delay the return to durable top-line expansion.

Definitive Healthcare Corp (DH) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%40%DH-51.45%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$143.60M
Dividend Yield
―
Average Volume (3M)
673.86K
Price to Earnings (P/E)
-0.9
Beta (1Y)
1.56
Revenue Growth
-6.18%
EPS Growth
10.48%
Country
US
Employees
682
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

Definitive Healthcare Corp Business Overview & Revenue Model

Company Description

Definitive Healthcare Corp. (DH), operating through its various subsidiaries, offers specialized commercial intelligence solutions for the U.S. healthcare industry. The company's services furnish essential data on healthcare providers and their activ...

Definitive Healthcare Corp Earnings Call Summary

Earnings Call Date:Aug 10, 2026(Q2-2026)|% Change Since:91.98%|Next Earnings Date:Mar 04, 2027
Earnings Call SentimentNeutral

The call conveyed a balanced message: clear near‑term top‑line pressures (Q2 revenue down 9% YoY, RPO and deferred revenue down double digits, professional services softness, and continued life sciences drag) alongside strong profitability, disciplined cost management, robust free cash flow (~$50M TTM), operational progress (integrations, win‑backs, digital activation growth), and product/AI momentum (Turbo pilot and AI embedding). Management tightened full‑year revenue guidance while raising profit/margin guidance and emphasized that improvements in net dollar retention and customer win‑backs underpin confidence in a return to growth over time.

Positive Updates

Profitability Above Guidance
Adjusted EBITDA of $14.6M in Q2 with a 26% margin, modestly above the high end of guidance; full-year adjusted EBITDA guidance raised to $57M–$59M (26%–27% margin) and midpoint increased by $1M.

Negative Updates

Top-Line Revenue Decline
Total revenue declined 9% YoY in Q2 to $55.2M; subscription revenue also down 9% YoY. Full‑year 2026 revenue guidance tightened to $220M–$222M, an expected decline of 8%–9% YoY.

Company Guidance

Definitive Healthcare said Q2 results informed a tightened outlook: Q2 revenue was $55.2M (‑9% YoY) with adjusted EBITDA $14.6M (26% margin), adjusted net income $7.5M ($0.05 non‑GAAP EPS), adjusted gross profit $44.2M (80% margin, down 12% YoY but +100bps ex‑one‑time credit), unlevered free cash flow $11.6M in Q2 and $50M TTM, deferred revenue $89M (‑12% YoY), total RPO down 18% YoY and current RPO $150M (‑12% YoY), and a TTM adjusted EBITDA→unlevered FCF conversion of 75% (down ~5pts). For Q3 they guide revenue $54–55M (‑8% to ‑10% YoY) with subscription revenue flat sequential, professional services expected to show double‑digit growth but below prior expectations, adjusted operating income $10.5–11.5M, adjusted EBITDA $13.5–14.5M (25–27% margin), adjusted net income $5.5–6.5M and EPS ~$0.04–0.05 on ~145M shares. Full‑year 2026 guidance is revenue $220–222M (‑8% to ‑9% YoY), adjusted operating income $45.5–47.5M, adjusted EBITDA $57–59M (26–27% margin), adjusted net income $27–29M and EPS $0.18–0.20 on ~145M shares; management tightened top‑line visibility, lowered professional services expectations, but raised the EBITDA midpoint by $1M and expanded margin guidance ~100bps.

Definitive Healthcare Corp Financial Statement Overview

Summary

High gross margins (TTM ~69.5%) and consistently positive operating/free cash flow support fundamentals, and leverage has improved sharply (debt-to-equity ~0.03). However, DH remains deeply unprofitable (TTM net margin ~-69%), ROE is very negative (~-78%), free cash flow is trending down, and TTM/2025 revenue is declining—keeping the financial profile below average overall.

Income Statement

28Negative

Balance Sheet

62Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue227.31M241.52M252.20M251.41M222.65M166.15M
Gross Profit158.02M183.28M197.47M203.93M180.03M125.47M
EBITDA-166.20M-141.86M-567.24M-241.23M26.23M23.08M
Net Income-157.25M-138.93M-413.12M-202.39M-7.22M-51.91M
Balance Sheet
Total Assets488.65M735.49M1.09B1.83B2.12B2.12B
Cash, Cash Equivalents and Short-Term Investments190.30M180.89M290.16M308.07M331.87M387.50M
Total Debt164.28M172.67M253.11M267.93M275.85M270.68M
Total Liabilities300.19M356.50M482.19M626.73M640.68M617.78M
Stockholders Equity145.33M281.11M444.38M861.36M948.92M871.31M
Cash Flow
Free Cash Flow24.19M37.06M45.85M38.21M27.25M18.48M
Operating Cash Flow37.16M53.78M58.20M41.19M35.58M25.21M
Investing Cash Flow52.65M153.88M-26.41M-31.78M-248.90M-46.73M
Financing Cash Flow-20.25M-150.79M-56.75M-25.58M-26.70M384.37M

Definitive Healthcare Corp Technical Analysis

Technical Analysis SentimentPositive
Last Price1.34

Price Trends

50DMA1.06Positive
100DMA0.92Positive
200DMA1.00Positive

Market Momentum

MACD0.07Negative
RSI67.50Neutral
STOCH67.59Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DH, the sentiment is Positive. The current price of 1.34 is above the 20-day moving average (MA) of 1.18, above the 50-day MA of 1.06, and above the 200-day MA of 1.00, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 67.50 is Neutral, neither overbought nor oversold. The STOCH value of 67.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DH.

Definitive Healthcare Corp Risk Analysis

Definitive Healthcare Corp disclosed 73 risk factors in its most recent earnings report. Definitive Healthcare Corp reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.If we do not continue to satisfy the Nasdaq continued listing requirements, our Class A common stock could be delisted from Nasdaq. Our ability to publicly or privately sell equity securities and the liquidity of our Class A common stock could be adversely affected if our Class A common stock is delisted.Q3, 2026
2.There can be no assurance that any definitive agreement will result from the non-binding acquisition proposal submitted by Advent or that any transaction will be consummated.Q3, 2026
3.We have received a notice of delisting or failure to satisfy a continued listing rule from Nasdaq. If we are unable to regain or maintain compliance, our Class A common stock could be delisted, which could adversely affect our stock price, liquidity, and ability to raise capital.Q2, 2026

Definitive Healthcare Corp Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
DOCSDOCS80Outperform$5.54B40.8914.81%―6.48%-43.66%
WAYWAY76Outperform$5.30B39.343.41%―21.43%9.80%
PHRPHR69Neutral$760.99M71.203.01%―12.93%―
DHDH56Neutral$194.65M-0.89-87.69%―-6.18%10.48%
HCATHCAT54Neutral$98.24M-0.46-128.24%―-13.88%-78.38%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
EVHEVH51Neutral$444.50M-0.88-129.54%―14.06%-189.46%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DHEVHPHRHCATDOCSWAYDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DHDefinitive Healthcare Corp. Class A1.34-1.26-48.46%
EVHEvolent Health Inc.3.930.246.50%
PHRPhreesia12.26-6.79-35.64%
HCATHealth Catalyst1.29-0.74-36.45%
DOCSDoximity, Inc.30.67-15.75-33.93%
WAYWaystar Holding Corp.27.54-7.25-20.84%

Definitive Healthcare Corp Corporate Events

Business Operations and StrategyRegulatory Filings and Compliance

Definitive Healthcare Holders Waive Tax Agreement Termination Rights

Positive
Sep 9, 2026

Definitive Healthcare disclosed that holders of its tax receivable agreement, including affiliates of Advent International, Spectrum Equity, 22C Capital and founder Jason Krantz, have irrevocably waived their right to receive an early termination pay...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026